SCHEMBL3477447

SCHEMBL3477447

CC(C)(C)C1CC(c2cc(Cl)ccc2O)CCN1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
RECQL P46063 1/20 0.34
PTGDR2 Q9Y5Y4 3/20 0.33
PTGDR Q13258 2/20 0.33
SHMT1 P34896 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
F2 P00734 1/20 0.33
ALOX15 P16050 1/20 0.33
SPR P35270 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476260 0.84 SIGMAR1 (0.37) MEN1KMT2APTGDR2RBP4
SCHEMBL1094791 0.78 PTGDR2 (0.45) MEN1KMT2ANR1H4PTGDR2PTGDR
SCHEMBL17223025 0.78 RBP4 (0.41) RBP4
SCHEMBL23705962 0.78 SIGMAR1 (0.42) MEN1KMT2APTGDR2RBP4
SCHEMBL38658417 0.74 FFAR2 (0.33) MEN1KMT2ASMN1; SMN2
SCHEMBL29136131 0.74 RIPK1 (0.49) KMT2AALDH1A1SMN1; SMN2
SCHEMBL26665054 0.73 SIGMAR1 (0.48)
SCHEMBL26665056 0.73 SIGMAR1 (0.48)
SCHEMBL4570999 0.73 F2 (0.32) TSHRF2
SCHEMBL3477814 0.73 MEN1 (0.39) MAOAMAOBMEN1KMT2ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 MAOA 2031/4885MAOB 2111/4885MEN1 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.